Cargando…
Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis
We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patie...
Autores principales: | Kehr, Sarah, Berg, Philipp, Müller, Susanne, Fiedler, Sarah A., Meyer, Britta, Ruppert-Seipp, Gabriele, Witzenhausen, Cornelia, Wolf, Marc E., Henkes, Hans H., Oberle, Doris, Keller-Stanislawski, Brigitte, Funk, Markus B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255460/ https://www.ncbi.nlm.nih.gov/pubmed/35790739 http://dx.doi.org/10.1038/s41541-022-00491-z |
Ejemplares similares
-
AZD-1222: Cerebral venous sinus thrombosis with thrombotic thrombocytopenia: case report
Publicado: (2022) -
Tozinameran: Cerebral venous sinus thrombosis and immune thrombotic thrombocytopenia: case report
Publicado: (2022) -
AZD-1222: Thrombotic thrombocytopenia causing cerebral venous sinus thrombosis and hepatic veins thrombosis: case report
Publicado: (2022) -
Ad26.COV2-S: Thrombotic thrombocytopenia and cerebral venous sinus thrombosis: case report
Publicado: (2021) -
AZD-1222: Immune thrombotic thrombocytopenia and cerebral sinus venous thrombosis: 2 case reports
Publicado: (2022)